We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Statin developers received positive news on the research front last week in the form of two clinical studies that indicate statin drugs help reduce the body’s level of c-reactive protein (CRP), which has been associated with increased risks of coronary disease.
The HHS did not work with industry to produce the vaccines and drugs necessary to respond to a biological or chemical terrorist attack, said the former head of the HHS office that oversees biodefense efforts.
Nearly three-quarters of all investigative drugs fail to make it through clinical trials, but the chances of a particular drug reaching the market decrease as the time to complete the trials increases, according to a new study that assesses the prospects of drugs in the pipeline.
While nearly three-quarters of all investigative drugs fail to make it through clinical trials, the chances of a particular drug reaching the market decrease as the time to complete the trials increases, according to a new study that assesses the prospects of drugs in the pipeline.
The FDA has delayed progress on its much-touted Critical Path Initiative, which aims to expedite the drug development process, as other issues have occupied the agency’s attention, including safety concerns about marketed drugs.
The results from all of Eli Lilly’s Phase I through Phase IV clinical trials of its marketed drugs are publicly accessible through Lilly’s online trial registry.
The American Health Information Management Association (AHIMA) has asked HHS Secretary Tommy Thompson to use any undesignated and/or unspent discretionary funds in the department’s budget to support HHS’ new Office of the National Coordinator for Health Information Technology (ONCHIT).
Up to 80 percent of clinical trials are delayed by three months or more because of difficulties in finding patients for the studies, according to experts who tout internet and online database recruiting as possible solutions to the problem.
Two recent clinical trials of cardiovascular disease drugs in black patients have shown promising results, and at least one drugmaker is conducting clinical trials that target heart treatments in other minority groups.
Drugmakers could reduce the size of their clinical trials and save millions of dollars in development costs by using predictive biomarkers for distinguishing promising drug candidates from likely failures, according to the FDA’s acting commissioner.